Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Innovent Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Innovent Dosed First Obese Subject in A Phase 2 Clinical Trial of IBI362

Contact the Supplier

Lead Product(s): IBI362

Therapeutic Area: Nutrition and Weight Loss Product Name: LY3305677

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2021

Details:

IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist used to assess the efficacy and safety of IBI362 in overweight or obese subjects in China.